학술논문
729MO Final results of the first-in-human clinical trial of the GDF-15 neutralizing antibody CTL-002 in combination with nivolumab in subjects with solid tumors relapsed/refractory to prior anti-PD1/PD-L1 treatment
Document Type
Abstract
Author
Source
In Annals of Oncology September 2022 33 Supplement 7:S876-S876
Subject
Language
ISSN
0923-7534